Over the past 45 years, the majority of deaths averted from breast, cervical, colorectal, lung, and prostate cancer were due to prevention and screening, rather than treatment advances, NCI researchers have found.
A new study led by NCI researchers shows that mutant RAS proteins help release a nuclear protein from a complex transported from the nucleus to the cytoplasm, kicking off a series of events that lead to the breakdown of a tumor suppressor protein.
New studies released by NCI’s Human Tumor Atlas Network explore the role of the tumor microenvironment and the immune system in promoting the spread of cancer and its resistance to treatment. The studies appear across several Nature journals.
NCI has launched myeloMATCH, a precision medicine treatment trial that will test treatment combinations targeting specific genetic changes in people with acute myeloid leukemia and myelodysplastic syndromes.
While new cancer diagnoses largely returned to pre-pandemic levels in 2021, they don’t account for the missed diagnoses in early 2020 that resulted from disruptions in cancer screening and other medical care.
A new study suggests, for men with West African genetic ancestry, living in a disadvantaged neighborhood was associated with a higher risk of prostate cancer. The researchers posit that chronic stress—such as from racial profiling, housing discrimination, and exposure to violence—may be a possible driver.
An NCI trial shows that giving patients pembrolizumab after surgery for high-risk muscle invasive bladder cancer doubles the median length of time that they remain cancer free, compared with observation alone after surgery.
A new cellular immunotherapy approach shrank tumors in 3 of 7 patients with metastatic colon cancer, in a small NCI clinical trial. Normal white blood cells from each patient were genetically engineered to produce receptors that recognize and attack their specific cancer cells.
A large analysis of data from nearly 400,000 healthy U.S. adults followed for more than 20 years has found no association between regular multivitamin use and lower risk of death.
More than half of clinical trial participants treated with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) had substantial tumor shrinkage. Of those, 38% had tumors that disappeared completely.
